Insights and Analysis

Proactive and forward-looking disclosure risks for pharma

22 January 2026
Judges gavel on wooden desk. Law firm concept.
Judges gavel on wooden desk. Law firm concept.

Jennifer Windom and Bolton Smith present the risks and considerations pharmaceutical and life sciences companies have to take when making proactive and forward-looking disclosure statements.

Read the full article here.

This article is published by Drug Discovery World.

Contacts

bio-image

Jennifer S. Windom

Partner

location Washington, D.C.

bio-image

Bolton Smith

Associate

location Washington, D.C.

View more

Related topics

Related countries

Load more

Related keywords

Load more

Articles you may be interested in

image_1
Insights and Analysis

DOJ Subpoenas, Scientific Exchange, and Deference to Doctors – What We Are Watching

04 December 2025
image_1
Insights and Analysis

The False Claims Act Guide: 2024 and the road ahead

13 February 2025
image_1
News

The False Claims Act Guide: 2023 and the road ahead

14 February 2024
image_1
News

The False Claims Act Guide: 2022 and the road ahead

14 March 2023
image_1
News

Public life sciences companies uniquely positioned as SOX retaliation defendants

14 June 2022
left_arrow
right_arrow

View more insights and analysis

arrow
arrow

Register now to receive personalized content and more!

 

Register
close
See benefits
Register